DSM Finalizes Martek Acquisition

HERLEEN, The NetherlandsDSM finalized its acquisition of Martek Biosciences Corporation for approximately US$1,087 million. The acquisition will help DSM grow in the area of healthy, natural ingredients for infant formula and other functional foods and beverages. In particular, this acquisition provides DSM with a strong platform of polyunsaturated fatty acids, including omega-3 DHA (docosahexaenoic acid) and Omega-6 ARA (arachidonic acid).

The integration of the two companies began when the deal was announced in Dec. 2010, but complete integration is now the focus of a dedicated integration team.

Feike Sijbesma, CEO/Chairman of the DSM Managing Board said: This is an important day for DSM, as we are acquiring an exciting business with a very strong market leading product portfolio in the field of nutrition. This acquisition fully fits with the new DSM, focusing on Life Sciences and Materials Sciences. We are very excited to welcome all employees of Martek to DSM. With the combined strength and track record of DSM and Martek, I strongly believe that we will be able to take this business to the next level.

Our attention is now fully focused on ensuring a smooth integration of the Martek business in a timely and efficient manner. Throughout this process, business continuity will remain a key priority for us and I am confident that our integration team is well positioned to ensure that it is business as usual for our customers and suppliers. We expect the integration will be made significantly easier by the companies familiarity with each other."